Alnylam Announces Extension of RNAi Therapeutics Collaboration with Novartis
News Jul 20, 2009
Alnylam Pharmaceuticals, Inc. has announced that Novartis has elected to extend the company’s RNAi therapeutics collaboration for a fifth and final planned year, through October 2010.
The landmark alliance was initiated in October 2005 and is focused on the discovery, development, and commercialization of RNAi therapeutics toward a defined number of Novartis-selected disease gene targets.
“We are thrilled that Novartis has once again elected to extend our alliance, this time for a fifth and final planned year,” said John Maraganore, Ph.D., Chief Executive Officer of Alnylam. “This is the second extension that Novartis has elected to make, which we believe reflects the success of our collaborative efforts as well as the scientific progress we have made in advancing our innovative technology to patients. Novartis has been an industry pioneer in recognizing the potential of RNAi therapeutics as a new class of medicines, and we look forward to continuing our work with them.”
In the Novartis-Alnylam collaboration, both companies are jointly responsible for RNAi discovery activities and Novartis is generally responsible for development and commercialization of RNAi therapeutic products. With the extension of the alliance term, Novartis will continue to fund collaboration research and development efforts conducted by Alnylam.
Novartis retains its rights and conditions as per the original 2005 agreement. This includes a right to exercise a non-exclusive platform from Alnylam, in exchange for certain payments due upon platform license exercise, as well as an undisclosed payment and future milestones and royalties.
Further, Novartis retains certain rights to purchase Alnylam equity up to its current ownership level which is approximately 13.4%.
How Environmental Pollutants and Genetics Work Together in Rheumatoid ArthritisNews
It is well known that individuals with a particular version of human leukocyte antigen have an increased risk for rheumatoid arthritis, but there has been growing interest in the role of environmental pollutants. In a new mouse study, researchers probed the relationship between the two.READ MORE
Southeast Asian Nomads Have Evolved to Hunt Fish UnderwaterNews
The human spleen can release oxygenated blood cells to allow more time underwater without breathing. A new study has identified that the "Sea Nomad" Bajau people of Indonesia have evolved larger spleens that would allow them to remain underwater for longer.READ MORE
Gene Therapy Could End Transfusions for Blood Disorder PatientsNews
Beta-thalassemia patients need a regular dose of red blood cells transfused into their body. A new gene therapy that edits faulty genes in the patients' cells could end this monthly ritual.READ MORE
Comments | 0 ADD COMMENT
International Conference on Epigenetics and Epitranscriptomics
Sep 17 - Sep 18, 2018